Healthcare / Drug Manufacturers - Specialty & GenericBSE
$720.40
-51.15 (-6.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-367.7M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
N/A
•EV/EBITDA
34.1x
↑ROE
-0.4%
↓Gross Margin
65.9%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-0.6%
FCF CAGR
—
FCF margin
-11.0%
FCF / Net income
24.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.34B · net income $-14.9M · FCF $-367.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.34B | $3.34B | $3.46B | $3.60B | $3.40B |
| Net Income | $-14.9M | $-14.9M | $172.0M | $754.2M | $361.7M |
| EBITDA | $129.2M | $129.2M | $326.1M | $1.04B | $596.2M |
| EPS | — | — | 30.14 | 132.15 | 63.39 |
| Gross Margin | 65.9% | 65.9% | 66.4% | 64.4% | 63.0% |
| Operating Margin | -1.3% | -1.3% | -1.1% | 11.4% | 10.7% |
| Net Margin | -0.4% | -0.4% | 5.0% | 20.9% | 10.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.03 | 0.01 | 0.02 |
| Current Ratio | 3.24 | 3.24 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-367.7M | $-367.7M | $-432.9M | $346.3M | $52.8M |
| Returns | |||||
| ROE | -0.4% | -0.4% | 4.4% | 19.7% | 11.6% |
| Valuation | |||||
| P/E | — | — | 27.74 | 9.08 | 8.45 |
| EV/EBITDA | 34.09 | 34.09 | 15.00 | 6.55 | 5.19 |
| P/B | 1.05 | 1.05 | 1.22 | 1.79 | 0.98 |
| Growth & Yield | |||||
| Revenue Growth | -3.5% | -3.5% | -4.0% | 6.0% | — |
| EPS Growth | — | — | -77.2% | 108.5% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.3%
Start / end P/E
n/dx → n/dx
EPS bridge
30.14 → n/d
Residual
-11.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.